Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Sitagliptin + Metformin; Drug: Rosiglitazone + Metformin

Study type: Observational

Funder types: Industry

Identifiers

NCT01332370

112611

Details and patient eligibility

About

This retrospective database study analyzed resource utilization and costs associated with sitagliptin (STG) in comparison with rosiglitazone (RSG) added to metformin (MET) monotherapy among adults with a diagnosis of diabetes who were continuously enrolled in a large US healthcare plan.

Enrollment: 5,391 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Continuously enrolled in the health insurance plan to ensure complete claims coverage
• At least 1 claim with a diagnosis of diabetes (ICD-9 250.xx)
• Aged 18 years or older at the index date
• At least 6 months of baseline period prior to the index date
• At least 1 claim for MET during the baseline period
• At least 180 days of continuous therapy with RSG+MET or STG+MET after the index date

Exclusion criteria

• At least 1 claim for insulin or sulfonylurea in the baseline period
• At least 1 claim with a diagnosis of congestive heart failure in the baseline period

Trial design

5,391 participants in 1 patient group

Adults with Type 2 Diabetes

Description:

Subjects with a diagnosis (ICD-9 code) of diabetes

Treatment:

Drug: Sitagliptin + Metformin

Drug: Rosiglitazone + Metformin